Philippe Aftimos
Overview
Explore the profile of Philippe Aftimos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1928
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Volders P, Aftimos P, Dedeurwaerdere F, Martens G, Canon J, Beniuga G, et al.
NPJ Precis Oncol
. 2025 Mar;
9(1):66.
PMID: 40065106
The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making for patients with advanced cancers. This multi-center...
2.
Metoikidou C, Karnaukhov V, Boeckx B, Timperi E, Bonte P, Wang L, et al.
Cell Rep Med
. 2025 Feb;
:101973.
PMID: 39983715
Chemotherapy combined with immune checkpoint blockade has shown clinical activity in breast cancer. Response, however, occurs in only a low proportion of patients. How the immune landscape of the tumor...
3.
Jhaveri K, Neven P, Casalnuovo M, Kim S, Tokunaga E, Aftimos P, et al.
N Engl J Med
. 2024 Dec;
PMID: 39660834
Background: Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (). Methods: In a...
4.
Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, et al.
J Clin Oncol
. 2024 Oct;
43(5):513-523.
PMID: 39442070
Purpose: Human epidermal growth factor receptor 2 (HER2)-targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop progressive disease with persistent HER2 expression. No definitive...
5.
Neven P, Stahl N, Vidal M, Martin M, Kaufman P, Harbeck N, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5304-5313.
PMID: 39377773
Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in...
6.
Jhaveri K, Lim E, Jeselsohn R, Ma C, Hamilton E, Osborne C, et al.
J Clin Oncol
. 2024 Sep;
42(35):4173-4186.
PMID: 39241211
Purpose: Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in mutant breast cancer. This phase Ia/b trial determined the recommended...
7.
Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061253
In the original article [...].
8.
Ignatiadis M, Poulakaki F, Spanic T, Brain E, Lacombe D, Sonke G, et al.
Eur J Cancer
. 2024 Jun;
207:114156.
PMID: 38861756
The European Breast Cancer Council (EBCC) traditionally identifies controversies or major deficiencies in the management of patients with breast cancer and selects a multidisciplinary expert team to collaborate in setting...
9.
Li B, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, et al.
Lancet Oncol
. 2024 May;
25(6):707-719.
PMID: 38710187
Background: Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate approved by the US Food and Drug Administration and the European Medicines Agency for HER2-mutant non-small-cell lung cancer. Few treatment options exist...
10.
Mileva M, de Vries E, Guiot T, Wimana Z, Deleu A, Schroder C, et al.
NPJ Breast Cancer
. 2024 Jan;
10(1):4.
PMID: 38184611
Efficacy of the human epidermal growth factor receptor (HER)2-targeting trastuzumab emtansine (T-DM1) in breast cancer (BC) relies on HER2 status determined by immunohistochemistry or fluorescence in-situ hybridization. Heterogeneity in HER2...